Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2014

Sartorius Reports 7.7% Revenue Growth for Fiscal 2013

  • Joachim Kreuzburg, Ph.D., CEO of the Sartorius Group, told a press conference that the company achieved all financial targets for fiscal 2013, including growth of 7.7% in consolidated sales revenue of €887.3 million (around $1.22 billion), up from €845.7 million (approximately $1.16 billion) a year ago. He also pointed out that Sartorius’ bioprocess solutions division expanded its portfolio for the biopharma market by acquisitions and its own product development.

    “In the lab products & services division, we launched a number of promising new product series and at the same time we phased out a few nonstrategic product lines,” he said.

    Dr. Kreuzburg noted that operating profit rose 7.1% and the company’s profit margin reached 19.5%. The number of employees grew to over than 6,000. Sartorius expects sales to grow approximately 8% to 10% in constant currencies for 2014, he added.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »